Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Barratt

Showing results (181-190 of 272) with videos related to

Pageof 28
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|April 13, 2023
Long-Term Outcomes in IgA NephropathyDavid Pitcher, Fiona Braddon, Bruce Hendry, et al.
Kidney International|March 26, 2017
Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working GroupHernán Trimarchi, Jonathan Barratt, Daniel C Cattran, et al.
Kidney Medicine|March 5, 2026
C3 Glomerulopathy Diagnosis, Current Treatments, and Emerging TherapiesMahtab Mashayekhi, Jonathan E Zuckerman, Jonathan Barratt, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 6, 2023
Targeting APRIL in the Treatment of IgA NephropathyChee Kay Cheung, Jonathan Barratt, Kevin Carroll, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|September 11, 2019
Peritoneal Ultrafiltration for Heart Failure: Lessons from a Randomized Controlled TrialHari Dukka, Philip A Kalra, Martin Wilkie, et al.
Kidney International Reports|December 22, 2025
DMX-200 in Patients With Primary Focal Segmental Glomerulosclerosis: Results of the Phase 2 ACTION2 TrialHiddo J L Heerspink, Alessia Fornoni, Lesley A Inker, et al.
Kidney International Reports|December 19, 2024
Scoping Review of Economic Analyses of Rare Kidney DiseasesBlake Angell, Siyuan Wang, Thomas Gadsden, et al.
The New England Journal of Medicine|October 26, 2024
Atrasentan in Patients with IgA NephropathyHiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.
Kidney International|June 28, 2025
Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathyJürgen Floege, Richard Lafayette, Jonathan Barratt, et al.
The New England Journal of Medicine|November 2, 2023
A Phase 2 Trial of Sibeprenlimab in Patients with IgA NephropathyMohit Mathur, Jonathan Barratt, Bobby Chacko, et al.
Pageof 28

Showing results (181-190 of 272) with videos related to

Sort By:
Pageof 28
Clinical Journal of the American Society of Nephrology : CJASN|April 13, 2023
Long-Term Outcomes in IgA NephropathyDavid Pitcher, Fiona Braddon, Bruce Hendry, et al.
Kidney International|March 26, 2017
Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working GroupHernán Trimarchi, Jonathan Barratt, Daniel C Cattran, et al.
Kidney Medicine|March 5, 2026
C3 Glomerulopathy Diagnosis, Current Treatments, and Emerging TherapiesMahtab Mashayekhi, Jonathan E Zuckerman, Jonathan Barratt, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 6, 2023
Targeting APRIL in the Treatment of IgA NephropathyChee Kay Cheung, Jonathan Barratt, Kevin Carroll, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|September 11, 2019
Peritoneal Ultrafiltration for Heart Failure: Lessons from a Randomized Controlled TrialHari Dukka, Philip A Kalra, Martin Wilkie, et al.
Kidney International Reports|December 22, 2025
DMX-200 in Patients With Primary Focal Segmental Glomerulosclerosis: Results of the Phase 2 ACTION2 TrialHiddo J L Heerspink, Alessia Fornoni, Lesley A Inker, et al.
Kidney International Reports|December 19, 2024
Scoping Review of Economic Analyses of Rare Kidney DiseasesBlake Angell, Siyuan Wang, Thomas Gadsden, et al.
The New England Journal of Medicine|October 26, 2024
Atrasentan in Patients with IgA NephropathyHiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.
Kidney International|June 28, 2025
Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathyJürgen Floege, Richard Lafayette, Jonathan Barratt, et al.
The New England Journal of Medicine|November 2, 2023
A Phase 2 Trial of Sibeprenlimab in Patients with IgA NephropathyMohit Mathur, Jonathan Barratt, Bobby Chacko, et al.
Pageof 28